ItalyItaly

Promoting and Sustaining Italian Proteome Science

08.05.2004

Milan - The Italian Proteome Society (IPSo) has been created in November 2003 as a tool for co-ordination, especially in Italy but in collaboration with other proteome societies in Europe and around the world. Founded by renowned Italian scientists the society has already acquired a large number of international sponsors and partners like Ciphergen, Bio-Rad and Chiron Vaccines as well as the British Electrophoresis Society and the Proteomics Group at Munich's Technical University.
IPSo's Aims
IPSo is a non-profit organization that aims to promote research and training in the field of proteome science in universities, in public research agencies, in industry, in hospitals, and in their research institutions as well as in all interested centers. Furthermore IPSo intends to sustain and promote teaching in all disciplines correlated with proteome science in universities, pre-university and post-university schools, and in any other suitable centre. It favours the development of technological innovation within the realm of the proteome science as well as the scientific communication by promoting and sustaining various collaboration forms among different laboratories at the national level, coupled to the organization of congresses and meetings.
For an efficient diffusion of proteome research, IPSo will establish a few laboratories for permanent education, with a possibility of official credits for the participants. These laboratories will have to be equipped not only with instruments for two-dimensional separations, but also with mass spectrometry facilities and bioinfor-matic instruments for protein identifi-cation in search engines and databases. Wherever possible, with limited-number participants, IPSo will aim at individual facilities with hands-on experimentation for each participant. Three of these labs will be created, located at strategic places from the North to the South of Italy.
Additionally, the Society aims at creating a capillary informatic network for establishing contacts among different laboratories dealing with similar research projects, so as to favour inter-laboratory cooperation and, whenever possible, the aggregation into larger research units. It is thus hoped to create greater opportunities among those consociated laboratories for access to public Italian and EU funding.
Finally, IPSo is born as a society representative of all scientific realities in the Italian territory, which will have full rights of expression within the society. This structure will be reinforced also with the creation of regional divisions which will have full freedom of disseminating proteomic science locally and aggregating regionally different scientific realities.
First Proteome Congress
IPSo will hold the First National Congress on Proteomics in Verona on May 27-29 (see EuroBiotechNews 4/04).
Contact
Antonucci Francesca, Campostrini Natascia,
Castagna Annalisa, Cecconi Daniela
Strada le Grazie 15, I-37134 Verona
Tel.: +39-045-802-7086
Fax: +39-045-802-7929
email: Ipsoit@netscape.net, www.ipsoc.it

ItalyItaly

07.03.2012

Toscana Biomarkers S.r.l has entered the market for biomarkers with its first diagnostic kit. In late January, the company from Siena signed a licence agreement with DIESSE Ricerche S.r.l, based in Genoa. DIESSE will produce and...

ItalyItaly

07.03.2012

Italian researchers have reprogrammed neonatal cardiomyocytes into iPSCs that can re-differentiate toward CMs more efficiently than either cardiac fibroblast-derived iPS cells or even ES cells. (Cell Death Differ.,...

ItalyItaly

09.01.2012

Rome – A cold virus isolated from chimpanzees might work as an vector for human vaccines. Adenoviruses are principally suitable as vectors for vaccines for their ability to induce strong immune responses. But as most humans have...

ItalyItaly

16.12.2011

Milan/Turku – Italian drug developer Newron SpA has had a roller-coaster ride in the last few months. First Merck Serono decided to drop its stake in the company’s Parkinson’s Disease candidate salfinamide, and returned the...

ItalyItaly

15.12.2011

Genoa/Irvine – Researchers from the universities at Genoa and Irvine (US) have patented a new compound that blocks removal of the endo­cannabinoid painkiller anandamide from the synaptic space by a selective transport system....

ItalyItaly

01.10.2011

Parma/Baranzate – Chiesi Farmaceutici Spa has said it will lengthen its long-term collaboration with NiKem Research, which is focused on developing treatments within the respiratory therapeutic area. The two drug developers have...

ItalyItaly

01.10.2011

Milan/Turku – Biotie Therapies ASA’s announcement that it had signed an agreement to acquire Newron Pharma­ceuticals S.p.A. for €45m is both good and bad news for the Italian biotechnology sector. While Italy is losing one of its...

ItalyItaly

19.08.2011

Como – Shares in Gentium SpA lost about a third of their value on Thursday after The Italian biopharmaceutical company withdrew a marketing application for its drug Defibrotide being used against complications related to stem...

ItalyItaly

01.08.2011

Milan/London – Italy’s MolMed SpA has signed a deal with UK-based pharmaceutical giant GlaxoSmithKline to develop a production process for a gene therapy against the rare ‘bubble boy disease’. Over the next two years, GSK will...

Displaying results 1 to 10 out of 181

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive-italy/article/promoting-and-sustaining-italian-proteome-science.html

Print Magazine

Product of the week

Products

Events

All Events

Partner-Events

Stock list

All quotes

TOP

  • 4SC0.94 EUR2.17%
  • ACTELION108.70 CHF0.00%
  • ADDEX3.07 CHF0.00%

FLOP

  • CYTOTOOLS31.45 EUR-0.47%
  • ACTELION108.70 CHF0.00%
  • ADDEX3.07 CHF0.00%

TOP

  • CYTOS0.28 CHF75.0%
  • EPIGENOMICS5.15 EUR45.9%
  • STRATEC BIOMEDICAL48.50 EUR21.7%

FLOP

  • BIOFRONTERA2.52 EUR-13.1%
  • CO.DON2.51 EUR-8.7%
  • ADDEX3.07 CHF-7.0%

TOP

  • SANTHERA91.30 CHF2585.3%
  • CO.DON2.51 EUR139.0%
  • BB BIOTECH181.25 EUR63.4%

FLOP

  • CYTOS0.28 CHF-91.8%
  • 4SC0.94 EUR-46.0%
  • MOLOGEN7.35 EUR-41.4%

No liability assumed, Date: 22.11.2014

Current issue

All issues